NRXP.US NRX Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
2.19 USD
Close of Nov 15, 2026
1.62 5.06
Market cap
USD 95.6M
P/E
-
P/B
2.90x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is NRXP.US undervalued?

Graham number

The Graham number of NRX Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NRX Pharmaceuticals Inc fundamental analysis

No fundamental analysis for NRX Pharmaceuticals Inc yet.

NRX Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NRX Pharmaceuticals Inc

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation an…

Full company profile